Long-Term Outcomes of Pancreaticoduodenectomy with Level 3 Dissection in Primary Resectable Pancreatic Cancer: A Prospective Observational Study with Propensity Score-Matched Analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038897

Enrollment

100

Registered

2026-01-06

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25.0

Interventions

Group 1: partielle Pankreatektomie ohne Level-III Dissektion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Suspicion of primarily resectable pancreatic head carcinoma - Suitable for both surgical procedures Patients =18 years of age at the time of signing the informed consent form - Written informed consent from the patient prior to the start of study-specific measures - Patient's capacity to consent to participation in the study

Exclusion criteria

Exclusion criteria: - Borderline or locally advanced pancreatic cancer - Evidence of distant metastases - Patient who is institutionalized due to a court order or official order - Patient only suitable for one of the two procedures

Design outcomes

Primary

Measure	Time frame
This study was an observational, prospective, single-center data collection study. All patients with ductal adenocarcinoma of the pancreas who underwent surgery at the UKA Aachen between 2019 and 2023 were included. These patients underwent Level III dissection surgery. Quality of life questionnaires were collected prospectively. This study group was compared with a historical group from 2015-2018. Propensity score matching was performed, and the patients were then compared using the log-rank test and Cox regression analysis. Translated with DeepL.com (free version)	—

Measure

Time frame

This study was an observational, prospective, single-center data collection study. All patients with ductal adenocarcinoma of the pancreas who underwent surgery at the UKA Aachen between 2019 and 2023 were included. These patients underwent Level III dissection surgery. Quality of life questionnaires were collected prospectively. This study group was compared with a historical group from 2015-2018. Propensity score matching was performed, and the patients were then compared using the log-rank test and Cox regression analysis. Translated with DeepL.com (free version)

—

Secondary

Measure	Time frame
- Morbidity (Clavien-Dindo classification grade 0-5) - Comprehensive Complication Index (0–100) - Blood loss (ml) - In-hospital mortality (surgery date/discharge date; yes/no) - 90-day mortality (death from any cause; yes/no) - Postoperative hospital stay (surgery date/discharge date) - Resected lymph nodes (number of lymph nodes) - Anastomotic leaks (yes/no) - Pancreatic fistulas (yes/no) - Lymph fistulas (yes/no) - Overall survival after 2 years - Recurrence-free survival Translated with DeepL.com (free version)	—

Measure

Time frame

- Morbidity (Clavien-Dindo classification grade 0-5) - Comprehensive Complication Index (0–100) - Blood loss (ml) - In-hospital mortality (surgery date/discharge date; yes/no) - 90-day mortality (death from any cause; yes/no) - Postoperative hospital stay (surgery date/discharge date) - Resected lymph nodes (number of lymph nodes) - Anastomotic leaks (yes/no) - Pancreatic fistulas (yes/no) - Lymph fistulas (yes/no) - Overall survival after 2 years - Recurrence-free survival Translated with DeepL.com (free version)

—

Countries

Germany

Contacts

Public ContactGeorg Wiltberger

Uniklinik RWTH Aachen, Klinik für Allgemein-, Viszeral- & Transplantationschirurgie

gwiltberger@ukaachen.de+492418038073

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026